Balance Sheet (Annual)
ORGS / Orgenesis, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.
All numbers are times 1,000 except per share units.
|Cash Equivalents At Carrying Value||1||0||51||1,314||4,168||891||3,519|
|Accounts Receivable Net Current||-||-||-||-||1,173||1,229||1,336|
|Prepaid Expense Current||1||28||37||105||1,118||779||841|
|Receivables Net Current||-||-||-||-||-||-||691|
|Prepaid Pension Costs||-||1||4||6||-||-||-|
|Derivative Assets Noncurrent||-||-||-||-||-||-||339|
|Property Plant And Equipment Net||-||8||13||13||4,296||4,573||5,104|
|Restricted Cash And Cash Equivalents||-||-||-||-||5||5||-|
|Intangible Assets Net Excluding Goodwill||-||-||-||-||16,653||15,050||15,051|
|Other Assets Noncurrent||-||-||-||-||53||70||78|
|Liabilities And Stockholders Equity|
|Short Term Bank Loans And Notes Payable||-||-||-||14||-||21||0|
|Accounts Payable Current||45||136||139||1,084||3,475||4,554||3,914|
|Accrued Liabilities Current||-||73||386||375||816||1,205||1,435|
|Employee Related Liabilities Current||-||76||155||626||1,348||1,680||2,961|
|Due To Related Parties Current||36||42||42||42||42||42||116|
|Advance Payment On Account Of Grant||-||-||-||85||307||243||1,719|
|Notes Payable Current||-||-||-||-||2,829||1,111||378|
|Deferred Revenue Current||-||-||-||-||1,216||1,273||3,611|
|Convertible Debt Current||-||-||-||-||-||2,541||2,780|
|Derivative Liabilities Current||-||-||-||-||1,533||76||-|
|Investments In Associate Net||-||-||-||-||-||12||0|
|Long Term Loans Payable||-||-||-||-||-||-||2,118|
|Convertible Debt Noncurrent||-||-||-||-||-||1,059||2,415|
|Warrants And Rights Outstanding||-||-||1,158||560||1,382||1,843||-|
|Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent||-||-||4||5||5||5||6|
|Derivative Liabilities Noncurrent||-||-||-||-||-||273||0|
|Deferred Income Taxes And Other Liabilities Noncurrent||-||-||-||-||3,327||1,862||690|
|Commitments And Contingencies||-||-||-||-||0||0||-|
|Redeemable Common Stock||-||-||-||-||21,458||0||-|
|Redeemable Non Controlling Interest||-||-||-||-||-||-||3,606|
|Common Stock Value||8||5||5||6||6||12||1|
|Additional Paid In Capital||47||4,850||8,635||13,153||14,229||41,605||55,334|
|Common Stock Share Subscribed But Unissued Subscriptions Receivable||-||-||-||-60||-1,251||0||-1,483|
|Accumulated Other Comprehensive Income Loss Net Of Tax||-||-||-||-18||-1,286||-1,205||1,425|
|Retained Earnings Accumulated Deficit||-||-||-||-16,179||-20,640||-29,834||-44,120|
|Liabilities And Stockholders Equity||2||48||114||2,249||38,748||33,487||39,872|
Peers - Pharmaceutical Preparations (2834)
ADMP / Adamis Pharmaceuticals Corp.
BSPM / Biostar Pharmaceuticals, Inc.
CAPR / Capricor Therapeutics, Inc.
CRBP / Corbus Pharmaceuticals Holdings, Inc.
CTRV / Contravir Pharmaceuticals Inc
CWBR / CohBar Inc.
DFFN / Diffusion Pharmaceuticals Inc.
EDNV / ENDONOVO THERAPEUTICS, INC.
EYEG / Eyegate Pharmaceuticals Inc.
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET